Precision Therapy for Brain Tumors in Hereditary Syndromes.

Area of Science:

• Oncology
• Genetics
• Neurology

Background:

• Monogenic hereditary cancer predisposition syndromes involve known initiating genetic events in tumor formation.
• Nervous system tumors in these syndromes present a unique opportunity for targeted treatment strategies.

Purpose of the Study:

• To evaluate the utility of targeted therapeutic agents for nervous system tumors in hereditary cancer predisposition syndromes.
• To discuss the current practice and future potential of targeted therapies in this patient population.

Main Methods:

• Review of current clinical practices and literature regarding targeted therapy use.
• Analysis of the rationale for employing targeted agents despite potential off-label indications.

Main Results:

• Targeted agents can be effectively utilized in patients with known genetic alterations driving tumor formation.
• Current practice involves using targeted therapy when standard treatments are inadequate or undesirable.

Conclusions:

• Targeted therapies represent a powerful treatment modality for nervous system tumors in hereditary cancer syndromes.
• The use of targeted agents is likely to expand, potentially becoming a first-line treatment option in the future.